Emerging Therapies in Diabetes: New Drugs and Innovative Remedies
Authors
-
Pankti Bhavikkumar Patel
Sharda School of Pharmacy, Pethapur, Gandhinagar, Gujarat 382610, Gujarat Technological University, Ahmedabad, India
-
Amar M. Raval
-
Helly Bhupendrabhai Patel
-
Krisha Hiteshbhai Patel
-
Poorv Patel
-
Tushar Prajapati
DOI:
https://doi.org/10.68163/ptr.2026.61Keywords:
Advanced drug delivery, complications, diabetes mellitus, emerging therapies, gestational diabetes, global burden, immunotherapy, insulin therapy, limitations of current treatments, oral hypoglycaemic agents, type 1 diabetes, type 2 diabetesAbstract
Diabetes mellitus is a chronic metabolic disorder with a rapidly increasing global prevalence, posing significant health and economic challenges. More than 500 million adults are currently affected worldwide, with projections indicating further increases, particularly in low- and middle-income countries. The disease manifests primarily as Type 1 diabetes, characterized by autoimmune destruction of pancreatic beta cells; Type 2 diabetes, driven by insulin resistance and beta-cell dysfunction; and gestational diabetes, which increases long-term metabolic risks for both mother and child. Despite advances in insulin formulations, oral hypoglycaemic agents and structured lifestyle interventions, current therapies remain limited and often fail to prevent long-term complications such as cardiovascular disease, nephropathy and neuropathy. These limitations underscore the urgent need for emerging therapies. Novel approaches, including stem cell transplantation, immunotherapy, gene editing and advanced drug delivery systems, are being actively explored, highlighting their potential to restore pancreatic function and reduce diabetes-related complications. Collectively, these innovations represent a paradigm shift toward more effective and potentially curative strategies in diabetes care.
Downloads
References
Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest. 2006;116(7):1802-1812. doi:10.1172/JCI29103. DOI: https://doi.org/10.1172/JCI29103
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022: A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2022;45(11):2753-2786. DOI: https://doi.org/10.2337/dci22-0034
DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-795. DOI: https://doi.org/10.2337/db09-9028
Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98-107. DOI: https://doi.org/10.1038/nri2925
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2019;157:107843. doi:10.1016/j.diabres.2019.107843. DOI: https://doi.org/10.1016/j.diabres.2019.107843
Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4(6):525-536. DOI: https://doi.org/10.1016/S2213-8587(15)00482-9
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-1705. DOI: https://doi.org/10.1016/S0140-6736(06)69705-5
Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058-1070. DOI: https://doi.org/10.1161/CIRCRESAHA.110.223545
Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392:958-971. DOI: https://doi.org/10.1056/NEJMoa2410819
American Diabetes Association Professional Practice Committee for Diabetes. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1). doi:10.2337/dc26-S009. DOI: https://doi.org/10.2337/dc26-S009
Pagliuca FW, Millman JR, Gürtler M, Segel M, Van Dervort A, Ryu JH, et al. Generation of functional human pancreatic β cells in vitro. Cell. 2014;159(2):428-439. DOI: https://doi.org/10.1016/j.cell.2014.09.040
Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013;152(5):1173-1183. DOI: https://doi.org/10.1016/j.cell.2013.02.022
Yu J, Zhang Y, Ye Y, DiSanto R, Sun W, Ranson D, et al. Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. Proc Natl Acad Sci U S A. 2015;112(27):8260-8265. doi:10.1073/pnas.1505405112. DOI: https://doi.org/10.1073/pnas.1505405112
Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56. DOI: https://doi.org/10.1038/s41591-018-0300-7
Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019;381(7):603-613. DOI: https://doi.org/10.1056/NEJMoa1902226
Khan MS, Bhutani U, Venugopal H, Saini AK, Naidu VR, Kollipara S. Emerging therapies in metabolic health: a comprehensive review of GLP-1, GIP, and glucagon agonists. J Pept Sci. 2026;32(2). doi:10.1002/psc.70083. DOI: https://doi.org/10.1002/psc.70083
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-2306. DOI: https://doi.org/10.1056/NEJMoa1811744
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-1446. DOI: https://doi.org/10.1056/NEJMoa2024816
Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27-36. DOI: https://doi.org/10.1038/nm.3761
Shapiro AMJ, Lakey JRT, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343(4):230-238. DOI: https://doi.org/10.1056/NEJM200007273430401
Velazco-Cruz L, Song J, Maxwell KG, Goedegebuure MM, Augsornworawat P, Hogrebe NJ, et al. Acquisition of dynamic function in human stem cell-derived β cells. Stem Cell Reports. 2019;12(2):351-365. DOI: https://doi.org/10.1016/j.stemcr.2018.12.012
Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819-823. DOI: https://doi.org/10.1126/science.1231143
Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839-848. DOI: https://doi.org/10.1056/NEJMoa1616011
Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, et al. A guide to deep learning in healthcare. Nat Med. 2019;25(1):24-29. DOI: https://doi.org/10.1038/s41591-018-0316-z
Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001;358(9277):221-229. DOI: https://doi.org/10.1016/S0140-6736(01)05415-0
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. DOI: https://doi.org/10.1056/NEJMoa2107519
Veiseh O, Doloff JC, Ma M, Vegas AJ, Tam HH, Bader AR, et al. Size- and shape-dependent foreign body immune response to materials implanted in rodents and non-human primates. Nat Mater. 2015;14(6):643-651. DOI: https://doi.org/10.1038/nmat4290
Karlsson FH, Tremaroli V, Nookaew I, Bergström G, Behre CJ, Fagerberg B, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498(7452):99-103. DOI: https://doi.org/10.1038/nature12198
Florez JC. Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool? Diabetologia. 2017;60(5):800-807. DOI: https://doi.org/10.1007/s00125-017-4227-1
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. DOI: https://doi.org/10.1056/NEJMoa1504720
Sattar A. Innovative therapeutic paradigms in diabetes mellitus: current progress and future directions. Pak Biomed J. 2026;9(1):3-10. DOI: https://doi.org/10.54393/pbmj.v9i1.1325
Chen JT, Dadheech N, Tan EHP, Ng NHJ, Koh MBC, Shapiro AMJ, et al. Stem cell therapies for diabetes. Nat Med. 2025;31(7):2147-2160. DOI: https://doi.org/10.1038/s41591-025-03767-8
Reichman TW, Markmann JF, Odorico J, Witkowski P, Fung JJ, Wijkstrom M, et al. Stem cell-derived, fully differentiated islets for type 1 diabetes. N Engl J Med. 2025;393(9):858-868. DOI: https://doi.org/10.1056/NEJMoa2506549
Hering BJ, Rickels MR, Bellin MD, Millman JR, Tomei AA, García AJ, et al. Advances in cell replacement therapies for diabetes. Diabetes. 2025;74(7):1068-1077. DOI: https://doi.org/10.2337/db25-0037
Grattoni A, Korbutt G, Tomei AA, García AJ, Pepper AR, Stabler CL, et al. Harnessing cellular therapeutics for type 1 diabetes mellitus: progress, challenges, and the road ahead. Nat Rev Endocrinol. 2025;21(1):14-30. DOI: https://doi.org/10.1038/s41574-024-01029-0
Li H, Chen C, Wang Y, Huang Y, Hu P, He L, et al. A meta-analysis on application and prospect of cell therapy in the treatment of diabetes mellitus. Stem Cell Res Ther. 2025;16:249. doi:10.1186/s13287-025-04377-4. DOI: https://doi.org/10.1186/s13287-025-04377-4
Kashbour M, Abdelmalik A, Yassin MNA, et al. Mesenchymal stem cell-based therapy for type 1 & 2 diabetes mellitus patients: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2025;17:189. doi:10.1186/s13098-025-01619-6. DOI: https://doi.org/10.1186/s13098-025-01619-6
Manikandan S, Hariprasad R, Bagepally BS. Efficacy and safety of stem cell therapy in patients with diabetes mellitus: a systematic review and meta-analysis. Syst Rev. 2026;15:75. doi:10.1186/s13643-025-03054-0. DOI: https://doi.org/10.1186/s13643-025-03054-0
Das SS, Balaji EV, Pai KSR. The future of diabetes mellitus management: therapeutic insights from gene and stem cell research. Gene Rep. 2025;40:102292. doi:10.1016/j.genrep.2025.102292. DOI: https://doi.org/10.1016/j.genrep.2025.102292
Smukler SR, Arntfield ME, Razavi R, Bikopoulos G, Karpowicz P, Seaberg R, et al. The adult mouse and human pancreas contain rare multipotent stem cells that express insulin. Cell Stem Cell. 2011;8(3):281-293. DOI: https://doi.org/10.1016/j.stem.2011.01.015
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet. 2024;404(10467):2077-2093. doi:10.1016/S0140-6736(24)02317-1. DOI: https://doi.org/10.1016/S0140-6736(24)02317-1
Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. 2025;24(8):631-650. DOI: https://doi.org/10.1038/s41573-025-01183-8
Movahednasab M, Dianat-Moghadam H, Khodadad S, Nedaeinia R, Safabakhsh S, Ferns G, et al. GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation. Diabetol Metab Syndr. 2025;17:60. doi:10.1186/s13098-025-01623-w. DOI: https://doi.org/10.1186/s13098-025-01623-w
Bornstein SR, Wright JF, Steenblock C. The promising potential of gene therapy for diabetes mellitus. Nat Rev Endocrinol. 2024;20:627-628. DOI: https://doi.org/10.1038/s41574-024-01030-7
Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 2013;153(4):910-918. DOI: https://doi.org/10.1016/j.cell.2013.04.025
Rezania A, Bruin JE, Arora P, Rubin A, Batushansky I, Asadi A, et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol. 2014;32(11):1121-1133. DOI: https://doi.org/10.1038/nbt.3033
Raval AM, Chaudhari KN, Arora B, Ukani A, Modh R, Choubisa K, et al. Emerging role of GLP-1 and dual incretin agonists in the management of type 2 diabetes mellitus: mechanisms, clinical evidence, dosing strategies, and future perspectives. Int J Med Pharm Res [Internet]. 2026 [cited 2026 Sep 26];7(3):357-370. Available from: https://ijmpr.in/article/emerging-role-of-glp-1-and-dual-incretin-agonists-in-the-management-of-type-2-diabetes-mellitus-mechanisms-clinical-evidence-dosing-strategies-and-future-perspectives-2997/
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Pankti Bhavikkumar Patel, Amar M. Raval, Helly Bhupendrabhai Patel, Krisha Hiteshbhai Patel, Poorv Patel, Tushar Prajapati
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
